Physician profile
Lam N Dao
NPI 1609936137
$3,369.80
in general payments reported to CMS, 2019-2025
17 companies · $557 in 2025
The $557 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $456 · 2021: $481 · 2022: $606 · 2023: $395 · 2024: $431 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $601.83 | 2019-2025 | Cequa |
| Alcon Vision LLC | $330.96 | 2020-2025 | Tryptyr, Precision7, Rocklatan |
| Oyster Point Pharma, INC. | $303.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $288.51 | 2019-2021 | |
| Abbvie INC. | $255.06 | 2022-2025 | Vuity, Lumigan |
| Dompe US, INC. | $245.54 | 2021-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $231.95 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $190.52 | 2019-2022 | |
| Coopervision INC. | $189.74 | 2019-2025 | Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $159.94 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $158.63 | 2022-2024 | Infuse, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $129.86 | 2019-2023 | |
| Allergan, INC. | $123.31 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $53.72 | 2020-2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $36.06 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $31.41 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lam Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.